title: Chlorocarbamate-mustard-linked 1,1,2-triphenylbut-1-enes with a selective antitumor activity on mammary tumors containing estrogen receptors.
abstract: A 1,1,2-triphenylbut-1-ene with a 4-OH group at one C-1 phenyl ring and a chlorocarbamate mustard moiety at the second C-1 ring (compound 3) was synthesized in order to obtain a "cytotoxic estrogen" with a specific antitumor effect on estrogen-receptor-containing tumors. This compound was tested in comparison to the carrier (compound 1) and a compound (2) having a carbamate mustard group on both C-1 phenyl rings. The estrogen receptor affinity of compound 3 was only about one-quarter lower than that of compound 1, but much higher than that of compound 2. Compounds 2 and 3 showed only partially irreversible binding to the receptor owing to their relatively low alkylating properties. The growth inhibition of the receptor-positive MCF-7 breast cancer cell line by compound 3, but not by compound 1 or 2, was more pronounced than the inhibition of the receptor-negative line MDA. In vivo the hormone-dependent, transplantable mammary tumor MXT M3.2 of the mouse was much better inhibited by compound 3 than its hormone-resistent line MXT OVEX. Compounds 1-3 had no antiestrogenic properties in the mouse, but estrogenic activity was in the order 1 greater than 3 greater than 2. From these results and because the antitumor activity of compound 3 was superior to that of compounds 1 and 2 in the hormone-dependent tumor models, a selective, receptor-mediated cytotoxic effect of compound 3 on estrogen-receptor-positive tumors in obvious.
authors.affiliation: Institut für Pharmazie, Universität Regensburg, Federal Republic of Germany.
authors.forename: M R
authors.initials: MR
authors.lastname: Schneider
authors.forename: M L
authors.initials: ML
authors.lastname: Schuderer
mesh_terms: D000475:Alkenes / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004337:Drug Carriers; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000032:analysis / Q000188:drug therapy*; D051379:Mice; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011960:Receptors, Estrogen / Q000032:analysis*
chemical_list: D000475:Alkenes; D000970:Antineoplastic Agents; D004337:Drug Carriers; D004967:Estrogens; D009588:Nitrogen Mustard Compounds; D011960:Receptors, Estrogen; C058080:1,1-bis(4-(N,N-bis-2-chloroethylcarbamoyloxy)phenyl)-2-phenylbut-1-ene; C058082:1-(4-(N,N-bis-2-chloroethylcarbamoyloxy)phenyl)-1-(4-hydroxyphenyl)-2-phenylbut-1-ene